GLPwatch
Papers (10386)
Page 137 of 174, ranked by citation count.
- Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes.
- Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.
- Exenatide in type 2 diabetes.
- Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.
- Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial.
- Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.
- Reactivity of N terminal histidine of peptides towards excipients/impurity of excipients: A case study of liraglutide excipient compatibility study.
- Fatal, Fulminant, Necrotizing Pancreatitis Associated With Recent Tirzepatide Initiation.
- Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.
- Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories.
- Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial.
- Liraglutide Suppresses Myocardial Fibrosis Progression by Inhibiting the Smad Signaling Pathway.
- Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.
- Mazdutide: First Approval.
- Liraglutide combined with HIIT preserves contractile apparatus and blunts the progression of heart failure in diabetic cardiomyopathy rats.
- The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.
- Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study.
- [Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)].
- Deciphering the Effects of Semaglutide Across the Glycemic Spectrum.
- Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.
- Comparing diabetes drugs--helping clinical decisions?
- Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis.
- Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.
- Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?
- Liraglutide promotes diabetic corneal epithelial and nerve regeneration by suppressing oxidative stress via the PI3K/AKT signalling pathway.
- Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
- In brief: GI effects of GLP-1 receptor agonists.
- Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.
- Case report: Tirzepatide for mitochondrial diabetes mellitus with a mutation at position 3271 and transient GAD antibody positivity.
- Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder.
- Shedding light on weight loss: A narrative review of medications for treating obesity.
- The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis.
- Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
- Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia.
- Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.
- Semaglutide may provide sustained weight loss for at least four years, study reports.
- Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes.
- The Impact of Liraglutide on Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
- Spatially diffuse cAMP signalling with oppositely biased GLP-1 receptor agonists in β-cells despite differences in receptor localisation.
- Dissecting Hidden Liraglutide Oligomerization Pathways via Direct Mass Technology, Electron-Capture Dissociation, and Molecular Dynamics.
- A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.
- Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
- SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.
- Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.
- <sup>68</sup>Ga-NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
- Hypothalamic RASA1/Ras/AKT/GnRH axis reprogramming mediates GLP-1RA's central rescue of PCOS HPG dysfunction.
- Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.
- Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
- Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.
- Can a monthly exenatide extended release regimen provide a therapeutic and cost benefit?
- Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.
- Incretin physiology and its role in type 2 diabetes mellitus.
- Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin.
- Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome.
- [Diabetic ketoacidosis after switching insulin for exenatide].
- A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes.
- Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes.
- [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
- Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
- The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?